Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries
Shivaprakash M. Rudramurthy, Martin Hoenigl, Jacques F. Meis, et al.
Mycoses (2021) Vol. 64, Iss. 9, pp. 1028-1037
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
Martin Hoenigl, Danila Seidel, Agostinho Carvalho, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 7, pp. e543-e552
Open Access | Times Cited: 387
COVID-19-associated fungal infections
Martin Hoenigl, Danila Seidel, Rosanne Sprute, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1127-1140
Open Access | Times Cited: 327
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Martin Hoenigl, Rosanne Sprute, Matthias Egger, et al.
Drugs (2021) Vol. 81, Iss. 15, pp. 1703-1729
Open Access | Times Cited: 293
Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World
Valliappan Muthu, Shivaprakash M. Rudramurthy, Arunaloke Chakrabarti, et al.
Mycopathologia (2021) Vol. 186, Iss. 6, pp. 739-754
Open Access | Times Cited: 201
COVID-19–associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India
Jesil Mathew Aranjani, Atulya Manuel, Habeeb Ibrahim Abdul Razack, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 11, pp. e0009921-e0009921
Open Access | Times Cited: 106
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India
Valliappan Muthu, Ritesh Agarwal, Atul Patel, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 9, pp. e240-e253
Open Access | Times Cited: 67
COVID-19–associated mucormycosis: a systematic review and meta-analysis of 958 cases
Laşin Özbek, A. Umur Topçu, Mehtap Manay, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 6, pp. 722-731
Open Access | Times Cited: 57
Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India
Valliappan Muthu, Ritesh Agarwal, Shivaprakash M. Rudramurthy, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 1, pp. 8-19
Open Access | Times Cited: 46
Invasive Fungal Infections Complicating COVID-19: A Narrative Review
Giacomo Casalini, Andrea Giacomelli, Annalisa Ridolfo, et al.
Journal of Fungi (2021) Vol. 7, Iss. 11, pp. 921-921
Open Access | Times Cited: 82
Pathogenesis of Respiratory Viral and Fungal Coinfections
Fabián Salazar, Elaine Bignell, Gordon D. Brown, et al.
Clinical Microbiology Reviews (2021) Vol. 35, Iss. 1
Open Access | Times Cited: 59
Current treatments against mucormycosis and future directions
Courtney Smith, Soo Chan Lee
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010858-e1010858
Open Access | Times Cited: 43
Immunity to fungi in the lung
Lena J. Heung, Darin L. Wiesner, Keyi Wang, et al.
Seminars in Immunology (2023) Vol. 66, pp. 101728-101728
Open Access | Times Cited: 36
Fungal infection profile in critically ill COVID-19 patients: a prospective study at a large teaching hospital in a middle-income country
Essamedin M. Negm, Mohamed Sorour Mohamed, Rehab Ahmed Rabie, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 32
Race and ethnicity: Risk factors for fungal infections?
Jeffrey D. Jenks, Chioma Inyang Aneke, Mohanad Al‐Obaidi, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 1, pp. e1011025-e1011025
Open Access | Times Cited: 29
Social determinants of health as drivers of fungal disease
Jeffrey D. Jenks, Juergen Prattes, Sebastian Wurster, et al.
EClinicalMedicine (2023) Vol. 66, pp. 102325-102325
Open Access | Times Cited: 24
Epidemiology and prognostic factors of mucormycosis in France (2012–2022): a cross-sectional study nested in a prospective surveillance programme
Laura Gouzien, Didier Che, Sophie Cassaing, et al.
The Lancet Regional Health - Europe (2024) Vol. 45, pp. 101010-101010
Open Access | Times Cited: 9
Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals
Danila Seidel, Michaela Simon, Rosanne Sprute, et al.
Mycoses (2021) Vol. 65, Iss. 1, pp. 103-109
Open Access | Times Cited: 49
Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis
Hariprasath Prakash, Anna Skiada, Raees A. Paul, et al.
Journal of Fungi (2021) Vol. 7, Iss. 8, pp. 616-616
Open Access | Times Cited: 48
Is there an association between zinc and COVID‐19–associated mucormycosis? Results of an experimental and clinical study
Valliappan Muthu, Mohan Kumar, Raees A. Paul, et al.
Mycoses (2021) Vol. 64, Iss. 10, pp. 1291-1297
Open Access | Times Cited: 41
COVID-19 associated mucormycosis – An emerging threat
Chien‐Ming Chao, Chih‐Cheng Lai, Wen‐Liang Yu
Journal of Microbiology Immunology and Infection (2022) Vol. 55, Iss. 2, pp. 183-190
Open Access | Times Cited: 31
Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives
Madhavan Yasasve, Kadambari Vijay Sai, Dilip Kumar Shanmugam, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3620-3620
Open Access | Times Cited: 28
Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open‐label randomized controlled trial
Valliappan Muthu, Ratnakara Rao Gogineni, Ritesh Agarwal, et al.
Mycoses (2023) Vol. 66, Iss. 8, pp. 688-696
Closed Access | Times Cited: 18
Multimodal analysis of the COVID‐19‐associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors
Anuradha Chowdhary, Nitesh Gupta, Sebastian Wurster, et al.
Mycoses (2023) Vol. 66, Iss. 6, pp. 515-526
Open Access | Times Cited: 17
Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India
Valliappan Muthu, Ritesh Agarwal, Shivaprakash M. Rudramurthy, et al.
Clinical Microbiology and Infection (2023) Vol. 30, Iss. 3, pp. 368-374
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top